- Live market news
- Stocks
- ABBV
AbbVie Inc
ABBVStockUSA
AbbVie Inc
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.
Key figures
- Previous close
- 281.12
- Open
- 283.29
- Day range
- 278.32 – 283.29
- 52-week range
- —
- Volume
- 835K
Latest news on ABBVranked by Oyticker for market impact
- 72Impact
ABBV/GMAB Epcoritamab + R-CHOP Shows PFS Benefit in Phase 3 DLBCL Trial
AbbVie and Genmab announced positive Phase 3 EPCORE DLBCL-2 results for epcoritamab combined with R-CHOP, demonstrating significant improvement in progression-free survival versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.
GMABABBVPharmaceuticalsBiotechnology - 35Impact
ABBV-295 Phase 1 data shows favorable tolerability; amylin analog advances toward clinical development
AbbVie presented Phase 1 multiple ascending dose (MAD) results for ABBV-295, a long-acting amylin analog, demonstrating acceptable tolerability and pharmacokinetic profile at EASD 2026. Early-stage safety and PK data support continued development in metabolic disease.
ABBVPharmaceuticalsBiotechnology - 62Impact
AbbVie Reports Positive Phase 2 Results for Zumilokibart in Atopic Dermatitis
AbbVie announced positive primary results from the Phase 2 APEX Part B dose-finding study of zumilokibart in moderate-to-severe atopic dermatitis, presented as a late-breaker at EADV 2026. The data advance the IL-13 inhibitor candidate toward Phase 3 development in a large dermatology market.
ABBVPharmaceuticalsDermatologyImmunology
In detailthe same figures as in Oyticker Charts
Performance
Ranges & volume
- Open
- 283.29
- Prev. close
- 281.12
Risk · 1 year
Seasonality
What ABBV filed
- 3 Nov 2026
- 2 Nov 2026
- 30 Oct 2026
- 15 Oct 2026
- 5 Oct 2026
- 3 Sept 2026
- 18 Aug 2026
- 5 Aug 2026
- 3 Aug 2026
- 31 Jul 2026
- 6 Jul 2026
- 22 Jun 2026
- 12 May 2026
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.